{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:16:17Z","timestamp":1790716577049,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.radonc.2026.111746","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T21:57:17Z","timestamp":1786917437000},"page":"111746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled phase III clinical trial"],"prefix":"10.1016","volume":"223","author":[{"given":"Qianyong","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faqiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-9636","authenticated-orcid":false,"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111746_b0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0010","doi-asserted-by":"crossref","unstructured":"Zhu QY, Zhao GX, Li Y, et al. Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. MedComm (2020). 2021. 2(2): 175-206.","DOI":"10.1002\/mco2.32"},{"key":"10.1016\/j.radonc.2026.111746_b0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111746_b0020","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190209","article-title":"Future of Radiotherapy in Nasopharyngeal Carcinoma","volume":"92","author":"Sun","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2026.111746_b0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","article-title":"Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival","volume":"21","author":"Lin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jnci\/dji084","article-title":"Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma","volume":"97","author":"Chan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2026.111746_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000205","article-title":"Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma","volume":"8","author":"Liu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0040","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0045","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis","volume":"24","author":"Petit","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1259331","article-title":"Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0055","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2147\/CMAR.S347864","article-title":"The failure patterns of Nasopharygeal Carcinoma after Intensity-Modulated Radiotherapy and Implications for Surveillance","volume":"14","author":"Tian","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.radonc.2026.111746_b0060","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0070","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","article-title":"Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial","volume":"75","author":"Chen","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0075","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00280-009-1152-0","article-title":"Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer","volume":"65","author":"Bae","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.radonc.2026.111746_b0080","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0085","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0090","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1186\/s12885-021-08381-8","article-title":"Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0095","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","article-title":"What is the best Treatment of locally Advanced Nasopharyngeal Carcinoma? an Individual Patient Data Network Meta-Analysis","volume":"35","author":"Ribassin-Majed","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2018.0026","article-title":"NCCN guidelines Insights: Head and Neck Cancers, Version 1.2018","volume":"16","author":"Colevas","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2026.111746_b0105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7314\/APJCP.2013.14.1.515","volume":"14","author":"Liang","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.radonc.2026.111746_b0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1055\/s-0042-1742724","article-title":"Comparison of two Standard Treatment Approaches in Locoregionally Advanced Nasopharyngeal Carcinoma","volume":"11","author":"Mohamad","year":"2022","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104686","article-title":"Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis","volume":"105","author":"Tang","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0120","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2274121","article-title":"The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis","volume":"24","author":"Zhong","year":"2023","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.radonc.2026.111746_b0125","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.18632\/aging.204246","article-title":"Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study","volume":"14","author":"Mu","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.radonc.2026.111746_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1475176","article-title":"Long-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study","volume":"14","author":"Zhao","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0135","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111746_b0140","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111746_b0145","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/annonc\/mdx770","article-title":"A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)","volume":"29","author":"Frikha","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0150","doi-asserted-by":"crossref","first-page":"100764","DOI":"10.18632\/oncotarget.21992","article-title":"Neoadjuvant chemotherapy with different dose regimens of docetaxel, cisplatin and fluorouracil (TPF) for locoregionally advanced nasopharyngeal carcinoma: a retrospective study","volume":"8","author":"Jin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2026.111746_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276651","article-title":"In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, platinum, and 5-Fluorouracil (TPF) followed by chemoradiation","volume":"18","author":"Jun","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2026.111746_b0160","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/BF02598295","article-title":"Proportional hazards (Cox) regression","volume":"8","author":"Katz","year":"1993","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.radonc.2026.111746_b0165","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12350-014-9908-2","article-title":"Survival analysis and regression models","volume":"21","author":"George","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.radonc.2026.111746_b0170","first-page":"239","article-title":"Partial residuals for the proportional hazards regression model","volume":"1","author":"David","year":"1982","journal-title":"Biometrika"},{"key":"10.1016\/j.radonc.2026.111746_b0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.radonc.2004.06.005","article-title":"Radiotherapy for nasopharyngeal carcinoma\u2013transition from two-dimensional to three-dimensional methods","volume":"73","author":"Teo","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ctrv.2009.01.002","article-title":"Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia","volume":"35","author":"Lu","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2026.111746_b0185","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jama.2022.13997","article-title":"Effect of Radiotherapy Alone vs Radiotherapy with concurrent Chemoradiotherapy on Survival without Disease Relapse in patients with Low-risk Nasopharyngeal Carcinoma: a Randomized Clinical Trial","volume":"328","author":"Tang","year":"2022","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2026.111746_b0190","first-page":"77","article-title":"Radiation-induced cancer after treatment for nasopharyngeal carcinoma: a study from a high prevalence area","volume":"61","author":"Cao","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.radonc.2026.111746_b0195","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/annonc\/mdy249","volume":"29","author":"Hong","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0200","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12885-020-06912-3","article-title":"The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0205","article-title":"Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.radonc.2026.111746_b0210","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111746_b0215","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.radonc.2026.111746_b0220","doi-asserted-by":"crossref","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN guidelines\u00ae Insights: Head and Neck Cancers, Version 1.2022","volume":"20","author":"Caudell","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2026.111746_b0225","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S1470-2045(23)00232-2","article-title":"Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"24","author":"Liu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0230","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0235","article-title":"Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer after Chemoradiation to Identify High-Risk patients for Adjuvant Chemotherapy: a Randomized Controlled Trial","author":"Chan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13014-019-1213-4","article-title":"The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma","volume":"14","author":"Peng","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105506","article-title":"Survival impact of increasing time to IMRT initiation following induction chemotherapy in nasopharyngeal carcinoma: a propensity score-matched analysis","volume":"122","author":"Zhou","year":"2021","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0250","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hed.27011","article-title":"Prognostic significance of wait time for radical radiotherapy in locoregionally advanced nasopharyngeal carcinoma","volume":"44","author":"Jiang","year":"2022","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2026.111746_b0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13014-022-02006-5","article-title":"Radiotherapy interruption due to holidays adversely affects the survival of patients with nasopharyngeal carcinoma: a joint analysis based on large-scale retrospective data and clinical trials","volume":"17","author":"Xu","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0260","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.7150\/jca.87901","article-title":"Development of a Nomogram for Progression-free Survival in patients with Stage II\/T3N0 Nasopharyngeal Carcinoma to Explore Different Treatment Modalities","volume":"14","author":"Yan","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0265","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ejca.2010.10.026","article-title":"Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials","volume":"47","author":"Lee","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0270","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2011.12.022","article-title":"Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"104","author":"Loong","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0275","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jjco\/hyx057","article-title":"Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3","volume":"47","author":"Kawahira","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0280","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hed.27333","article-title":"A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001)","volume":"45","author":"Yildirim","year":"2023","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2026.111746_b0285","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.22.00327","article-title":"Final overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: a Multicenter, Randomized phase III Trial","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0290","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1002\/ONCO.13520","article-title":"Meta-Analysis on Induction Chemotherapy in locally Advanced Nasopharyngeal Carcinoma","volume":"26","author":"Man\u00e9","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2026.111746_b0295","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fonc.2020.00119","article-title":"Evaluation of the National Comprehensive Cancer Network and European Society for Medical Oncology Nasopharyngeal Carcinoma Surveillance guidelines","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0300","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2021.03.051","article-title":"Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: results of a randomised phase II AGMT trial","volume":"151","author":"Keil","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2021.07.034","article-title":"Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients","volume":"156","author":"Szturz","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0310","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1186\/s12885-022-10306-y","article-title":"Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial","volume":"22","author":"Luo","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111746_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103986","article-title":"Induction chemotherapy in locally advanced head and neck cancers, is there a best choice","volume":"186","author":"Mahdavi","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2026.111746_b0320","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/07420528.2017.1397684","article-title":"A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy","volume":"35","author":"Zhang","year":"2018","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.radonc.2026.111746_b0325","article-title":"Long-term survival, toxicities, and the role of chrono-chemotherapy with different infusion rates in locally advanced nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy: a retrospective study with a 5-year follow-up","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0330","first-page":"59","article-title":"Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): an update on 26 trials and 7080 patients","volume":"32","author":"Blanchard","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111746_b0335","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111746_b0340","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2025.01.014","article-title":"Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: a multicenter phase 2 PLATINUM trial","volume":"43","author":"Xu","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2026.111746_b0345","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2025.1132","article-title":"Adjuvant PD-1 Blockade with Camrelizumab for Nasopharyngeal Carcinoma: the DIPPER Randomized Clinical Trial","volume":"333","author":"Liang","year":"2025","journal-title":"J Am Med Assoc"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:36:24Z","timestamp":1790714184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026005852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":69,"alternative-id":["S0167814026005852"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111746","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled phase III clinical trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111746"}}